Search
Patisiran
go.drugbank.com/drugs/DB14582ApprovedOnpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.
Cortisone acetate
go.drugbank.com/drugs/DB01380ApprovedInvestigational[A226295] Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory
Romosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalRomosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapie...
Abarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnSynthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes.
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene.